HIGHLIGHTS
- What: The cisplatin-alone group in the study seemed to have done much worse than what was reported in the EMBRACE I trial , which may be related to the higher clinical stage of the patients in the groups the authors enrolled. This study compared the efficacy and safety of three chemotherapy regimens of single-agent cisplatin, paclitaxel plus cisplatin, and nab-paclitaxel plus cisplatin combined with radiotherapy in the treatment of LACC.
- Who: Adverse events (AEs and collaborators from the Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Jiangsu Road, Qingdao, China have . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.